The participants in this study are under the age of 18 and are currently being monitored by the audiology clinic in the Department of Otolaryngology at the UIHC due to cancer treatment. The purpose of this research study is to see if a new OAE test can detect hearing loss earlier in children with cancer. Approximately 30 people will take part in this study conducted by investigators at the University of Iowa. Study involvement will last for as long as hearing is monitored for cancer treatment at the audiology clinic.
Shawn Goodman, 319-335-8700
Participants in this study have acute myeloid leukemia (AML) that has relapsed, has been difficult to treat, or is a very difficult to treat type of AML. AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd out the normal cells of the bone marrow. They may flood the bloodstream and invade vital organs. This study is for subjects that would ordinarily be offered a stem cell transplant (SCT; also known as hematopoietic cell transplantation or bone marrow transplant). AML patients might receive a stem cell transplant as part of standard therapy if: --Chemotherapy treatment is not destroying enough of their leukemia cells. This is called -refractory AML-. --Certain genetic factors are found in the blast cells --AML has gone away and then comes back (called relapsed AML).
Julie de la Garza 319-356-3749
Participants in this study have extra-ocular retinoblastoma, which is a cancer of the eye. The main purpose of this study is to find out whether this therapy will cure more subjects than therapies used in the past. Investigators will also study how well the study treatment makes the tumor shrink or disappear, and the side effects of the treatments. About 30 people will take part in this study overall. Approximately 5 subjects will participate at the University of Iowa. Study treatment will last about 6 months.
Julie de la Garza, 319-356-3749
Participants in this study have been diagnosed with acute lymphoblastic leukemia (ALL) or a cancer of the immune system tissue. The purpose of this study is test effectiveness of adding a drug called bortezomib to the standard therapy for relapsed ALL. Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. Study involvement will last approximately 15 weeks.
Participants in this study have been diagnosed with neuroblastoma or a neuroendocrine tumor. The purpose of this research study is to assess the safety and effectiveness of the combination of retinoic acid and Onalta® in treating your neuroblastoma or neuroendocrine tumor. Approximately 60 people will take part in this study conducted by investigators at the University of Iowa. Study involvement is life long with treatment lasting approximately 18-24 weeks.
M. Sue O'Dorisio, 319-356-7873
Copyright © 2013 The University of Iowa. All Rights Reserved.